Please use this identifier to cite or link to this item:
Title: Sentinel node identification with [99mTc]-tilmanocept SPECT/CT: a pictorial essay of clinical applications
Authors: Alongi, Pierpaolo
Garau, Ludovico Maria
Albalá González, Maria Dolores
Zucchetta, Pietro
Manca, Gianpiero
Margolin, Gregori
Vidal-Sicart, Sergi
Keywords: Lymphatic mapping;Lymphoseek;Sentinel node;SPECT/CT;[99mTc]-tilmanocept
Issue Date: 1-Aug-2020
Journal: Clinical and Translational Imaging 
© 2020, Italian Association of Nuclear Medicine and Molecular Imaging. Introduction: The recently developed radiopharmaceutical for sentinel node depiction is the mannose derivate Tilmanocept (Lymphoseek®). [99mTc]-tilmanocept, as a receptor-binding molecular imaging agent, has been approved by the US Food and Drug Administration and European Medicines Agency in 2014 for lymphatic mapping and lymph-node localization in breast cancer, melanoma, clinically node-negative squamous cell carcinoma of the oral cavity, and other solid tumors. Methods: Selected patients were enrolled in a retrospective study on the use of [99mTc]-tilmanocept planar scintigraphy, and SPECT/CT in melanoma, oral and breast cancer. Results: In this pictorial review, we present, in a clinical series of nine patients, the most commonly observed SLN identification findings and the related benefits using planar scintigraphy and SPECT/CT [99mTc]-tilmanocept in melanoma, oral and breast cancer. Discussion: [99mTc]-tilmanocept SPECT/CT resulted in an excellent choice for preoperative lymphatic mapping and presented an optimal biodistribution with a rapid injection-site clearance and persistent SLN retention that could lead to improved accuracy of sentinel node identification in selected cases of melanoma, oral and breast cancer.
ISSN: 22815872
DOI: 10.1007/s40336-020-00373-1
Appears in Collections:Articles

Show full item record

Page view(s) 1

checked on Oct 23, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.